Parameter
| Biomarker | CTNNB1 mutation | Full name | Catenin beta-1 gene mutation | Molecular Type | Nucleic acid (DNA mutation) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis and prediction of treatment response | ||
| Disease | Hepatocellular Carcinoma (HCC) | Disease Subtypes | / | ||
| Organ | - Liver | Test Sample / Technology Platform | Tumor tissue /ctDNA (NGS, digital PCR) | ||
| Pathobiological Mechanisms | Encoding protein beta serial, mutations can lead to Wnt pathways activated continuously, promoting tumor proliferation | ||||
| Clinical Availability Status | The validation: mutant atezolizumab + bevacizumab therapy in patients with OS is shorter | ||||
| Notes and Dynamics | Is immune to potential biomarkers for the treatment of drug resistance | ||||